Targeting the translation machinery in cancer
The DOI matches its Crossref record; 291 of the 291 references it cites were found in a registry or an index.
Abstract
Dysregulation of mRNA translation is a frequent feature of neoplasia. Many oncogenes and tumour suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumour cells, independent of the genetic make-up of the cancer. Therefore, therapeutic agents that target components of the protein synthesis apparatus hold promise as novel anticancer drugs that can overcome intra-tumour heterogeneity. In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The natural product, silvestrol, and related compounds are selective and potent inhibitors of the RNA helicase and translation initiation factor eIF4A (Eukaryotic Translational Initiation Factor 4A, also known as DDX2) [20].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [20]
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [38]
In the citing paper
“Many direct eIF4A/eIF4F mRNA targets have been identified and often encode proteins that drive proliferation, metastasis, and survival (11, 14, 15).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [14]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Research works printed but not linked: 5
- Hershey, J. W. B., Sonenberg, N. & Mathews, M. in Protein Synthesis and Translational Control (eds Hershey, J. W. B. et al.) (Cold Spring Harbor Laboratory Press, 2012)
- Pianese, G. Beitrag zur histologie und aetiologie der carcinoma histologische und experimentelle. Beitr. Pathol. Anat. Allg. Pathol. 142, 1–193 (in German) (1896). First evidence that dysregulated translation has a major role in cancer by demonstrating that cancer cells have hypertrophic and irregularly shaped nucleoli.
- De Benedetti, A. et al. CHO cells transformed by the translation factor elF-4E display increased c-Myc expression, but require overexpression of Max for tumorigenicity. Mol. Cell. Diff. 2, 347–371 (1994).
- Ron, D. & Harding, H. in Translational Control in Biology and Medicine Ch. 13 (eds Matthews, M. B. et al.) (Cold Spring Harbor Laboratory Press, 2007).
- Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
Cited by
Items 401–500 of 899
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia
Li, W., Zhao, Y., Wu, D., Chen, Z., Qing, Y., Yang, F., Ji, F., Zhang, L., Sau, L., Chen, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv7648 · Cited by 20
“Dysregulated mRNA translation is a hallmark of cancer, typically driven by oncogenic pathways, making it an attractive target for anti-cancer therapies to overcome intratumor heterogeneity ( 42 ).”
Cao, C., Yu, H., Wu, F., Qi, H., & He, J. (2017) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-017-9734-8 · Cited by 20
Translation reprogramming by eIF3 linked to glioblastoma resistance
Bertorello, J., Sesen, J., Gilhodes, J., Evrard, S., Courtade-Saïdi, M., Augustus, M., Uro‐Coste, E., Toulas, C., Moyal, E. C., Seva, C., et al. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa020 · Cited by 20
Xu, C.-Z., Shen, Y., Shi, Y., Zhang, M., & Zhou, L. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02578-y · Cited by 20
“Deregulation of oncogene and tumor suppressor mRNA translation is a frequent feature of cancer [4, 5], and translational regulation has been proposed as a potential therapeutic cancer target [6, 7].”
BackgroundZhuo, C., & Fürstner, A. (2016) · Angewandte Chemie · doi:10.1002/ange.201602125 · Cited by 20
eEF1A1 promotes colorectal cancer progression and predicts poor prognosis of patients
Fan, A., Zhao, X., Liu, H., Li, D., Guo, T., Zhang, J., Duan, L., Cheng, H., Nie, Y., Fan, D., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4848 · Cited by 20
Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors
Cao, Y., Ye, Q., Ma, M., & She, Q. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112764 · Cited by 20
Pharmacologic Inhibition of EIF4A Blocks NRF2 Synthesis to Prevent Osteosarcoma Metastasis
Lizardo, M. M., Hughes, C. S., Huang, Y. Z., Shyp, T., Delaidelli, A., Zhang, H., Shaool, S. S., Renner, A. F., Burwag, F., Sayles, L. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1317 · Cited by 20
“…(20), we wondered whether members of the eukaryotic initiation factor 4F (EIF4F) complex, namely EIF4G, EIF4A, and EIF4E, might also influence the translation of metastasis-associated mRNA transcripts, given that deregulation of these factors is implicated in many different cancer types (15).”
Querido, J. B., Sokabe, M., Díaz‐López, I., Gordiyenko, Y., Zuber, P. K., Du, Y., Albacete-Albacete, L., Ramakrishnan, V., & Fraser, C. S. (2024) · Nature Communications · doi:10.1038/s41467-024-50672-8 · Cited by 20
“In addition, the functional role of the RRMs located in the N-terminal domain (NTD) of Pdcd4 remain unknown.”
BackgroundRegulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer
Xie, J., Kusnadi, E. P., Furic, L., & Selth, L. A. (2021) · Cancers · doi:10.3390/cancers13133254 · Cited by 20
“These differences in translational programs of normal and neoplastic cells could yield a therapeutic window to selectively eradicate cancer cells by targeting translational machinery, while causing minimal toxicity [23].”
BackgroundInfluentialCytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway
Zhao, Z., Chu, W., Zheng, Y., Wang, C., Yang, Y., Teng, X., Yang, X., Zhang, W. Y., Ding, X., Li, G., et al. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00800-4 · Cited by 20
Translational Regulation by eIFs and RNA Modifications in Cancer
Zhang, L., Zhang, Y., Zhang, S., Qiu, L., Zhang, Y., Zhou, Y., Han, J., & Xie, J. (2022) · Genes · doi:10.3390/genes13112050 · Cited by 20
Chen, J., Xu, X., & Chen, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.124 · Cited by 20
Quantitative analysis of global protein stability rates in tissues
McClatchy, D. B., Martínez-Bartolomé, S., Gao, Y., Lavallée-Adam, M., & Yates, J. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-72410-y · Cited by 19
FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis
Francis, J. W., Hausmann, S., Ikram, S., Yin, K., Mealey-Farr, R., Flores, N. M., Trinh, A. T., Chasan, T., Thompson, J., Mazur, P. K., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.02.037 · Cited by 19
FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
Su, D., Wang, R., Chen, G., Ding, C., Liu, Y., Tao, J., Wang, Y., Qiu, J., Luo, W., Weng, G., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3638 · Cited by 20
Salvi, N., Papadopoulos, E., Blackledge, M. J., & Wagner, G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201603254 · Cited by 19
Pesce, E., Miluzio, A., Turcano, L., Minici, C., Cirino, D., Calamita, P., Manfrini, N., Oliveto, S., Ricciardi, S., Grifantini, R., et al. (2020) · Cells · doi:10.3390/cells9010172 · Cited by 19
Role of EIF4G1 network in non‐small cell lung cancers (NSCLC) cell survival and disease progression
Valle, L. D., Dai, L., Lin, H., Lin, Z. N., Chen, J., Post, S. R., & Qin, Z. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16307 · Cited by 19
Fang, C., Xie, H., Zhao, J. J., Wang, W., Hou, H., Zhang, B., Zhou, D., & Geng, X. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001074 · Cited by 19
Integrated Analysis of Nine Prognostic RNA-Binding Proteins in Soft Tissue Sarcoma
Lin, L., Liu, Z., Tian, J., Zhang, X., Zhang, Y., Yang, M., Zhong, H.-C., Fang, W., Wei, R., & Hu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633024 · Cited by 19
Subeha, M. R., Goyeneche, A. A., Bustamante, P., Lisio, M. A., Burnier, J. V., & Telleria, C. M. (2021) · Cancers · doi:10.3390/cancers14010099 · Cited by 18
“This is a polypeptide chain translation initiator factor that limits protein synthesis under conditions of cellular stress bas d on its capacity to become phosphorylated on serine 51 [46], thus limiting the availability of eIF2α needed for translation initiation [47].”
BackgroundeIF4F-mediated dysregulation of mRNA translation in cancer
Amiri, M., Mahmood, N., Tahmasebi, S., & Sonenberg, N. (2025) · RNA · doi:10.1261/rna.080340.124 · Cited by 18
“As the role of mRNA translational control in cancer has been extensively reviewed (Bhat et al. 2015; Robichaud et al. 2019; Xu and Ruggero 2020; Fabbri et al. 2021; Bartish et al. 2023), this article summarizes current advancements in the field and strategies to target eIF4F-mediated dysregulated…”
Self-citationXu, X. M., Huang, Z., Han, H., Yu, Z., Ye, L., Zhao, Z., Qian, Y., Li, Y., Zhao, R., Zhang, T., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217566 · Cited by 18
Chan, K. P., Gao, Y., Goh, J. X., Susanti, D., Yeo, E. L. L., Chao, S., & Kah, J. C. Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15269 · Cited by 18
Ortega, E., Ballester, F. J., Hernández-García, A., Hernández‐García, S., Guerrero‐Rubio, M. A., Bautista, D. K. M., Santana, M. D., Gandía‐Herrero, F., & Ruiz, J. (2020) · Inorganic Chemistry Frontiers · doi:10.1039/c9qi01704f · Cited by 18
Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma
Skofler, C., Kleinegger, F., Krassnig, S., Birkl-Toeglhofer, A. M., Singer, G., Till, H., Benesch, M., Cencic, R., Porco, J. A. J., Pelletier, J., et al. (2021) · Cells · doi:10.3390/cells10020301 · Cited by 18
Self-citationRelaxed initiation pausing of ribosomes drives oncogenic translation
Dong, L., Mao, Y., Zhou, A., Liu, X., Zhou, J. L., Wan, J., & Qian, S. (2021) · Science Advances · doi:10.1126/sciadv.abd6927 · Cited by 18
eIF3 interacts with histone H4 messenger RNA to regulate its translation
Hayek, H., Gross, L., Janvier, A., Schaeffer, L., Martin, F., Eriani, G., & Allmang, C. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100578 · Cited by 18
“p ul ld ow n HisGST-eIF3c(1-318) HisGST-eIF3c(319-913) HisGSTeIF3c(1-318) HisGSTeIF3c(319-913) In”
BackgroundInfluentialTargeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
Romagnoli, A., Maracci, C., D’Agostino, M., Teana, A. L., & Marino, D. D. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.20 · Cited by 18
Translational alterations in pancreatic cancer: a central role for the integrated stress response
Shin, S., Solórzano, J., Liauzun, M., Pyronnet, S., Bousquet, C., & Martineau, Y. (2022) · NAR Cancer · doi:10.1093/narcan/zcac031 · Cited by 18
“In other cancers, activation of these pathways has been largely described to induce dysregulation of protein synthesis through translation of a subset of mRNAs encoding tumor-promoting and survival factors (5,12).”
BackgroundsST2 translation is regulated by FGF2 via an hnRNP A1-mediated IRES-dependent mechanism
Kunze, M. M., Benz, F., Brauß, T. F., Lampe, S., Weigand, J. E., Braun, J., Richter, F. M., Wittig, I., Brüne, B., & Schmid, T. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.05.005 · Cited by 18
Olejniczak, S. H., Rocca, G. L., Radler, M. R., Egan, S. M., Xiang, Q., Garippa, R. J., & Thompson, C. B. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.01011-15 · Cited by 18
“Transcripts associated with cell growth and proliferation often contain complex 5= UTRs, allowing for an additional level of translational regulation by the RNA helicase eIF4A (8).”
BackgroundInfluentialSong, J. M., Gallagher, E. E., Menon, A., Mishra, L. D., & Garner, A. L. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob01041f · Cited by 18
Blagosklonny, M. V., & Gudkov, A. V. (2010) · Oncotarget · doi:10.18632/oncotarget.8305 · Cited by 18
Mudaliar, P., Pradeep, P., Abraham, R., & Sreekumar, E. (2021) · Journal of General Virology · doi:10.1099/jgv.0.001629 · Cited by 17
Anderle, N., Schäfer-Ruoff, F., Staebler, A., Kersten, N., Koch, A., Önder, C. E., Keller, A., Liebscher, S., Hartkopf, A. D., Hahn, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02782-2 · Cited by 17
“…of TNBC-PDMs consistent with those in the literature, characterized by upregulated PI3K/Akt and MAPK/RTK signaling [53, 63, 64, 98] with overexpressed proteins associated with integrated stress response [99–102], higher relapse rates, mortality [64, 103, 104], tumor growth and EMT [29, 105–107].”
BackgroundThe highs and lows of ionizing radiation and its effects on protein synthesis
Tamaddondoust, R. N., Wang, Y., Jafarnejad, S. M., Graber, T. E., & Alain, T. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110169 · Cited by 17
Alam, M. M., Shima, H., Matsuo, Y., Long, N. C., Matsumoto, M., Ishii, Y., Sato, N., Sugiyama, T., Nobuta, R., Hashimoto, S., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102084 · Cited by 17
Narayan, S., Raza, A., Mahmud, I., Koo, N., Garrett, T. J., Law, M. E., Law, B. K., & Sharma, A. K. (2021) · iScience · doi:10.1016/j.isci.2022.104518 · Cited by 17
“The first step in the cap-dependent translation initiation is the assembly of the trimolecular cap-binding complex, eIF4F, at the 5’UTR of the mRNA bound to the ribosome (Bhat et al., 2015).”
BackgroundmTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL
Vo, T.-T. T., Lee, J. S., Nguyen, D. M., Lui, B., Pandori, W., Khaw, A., Mallya, S., Lu, M., Müschen, M., Konopleva, M. Y., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0024 · Cited by 17
“The 4E-BP-eIF4F axis downstream of mTORC1 regulates protein translation and cell-cycle progression (34, 35).”
BackgroundWang, S., Zang, J., Huang, M., Guan, L., Xing, K., Zhang, J., Liu, D., & Zhao, L. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102971 · Cited by 17
“Western blot assays indicated that 6g suppressed the expression of Mcl-1, p-eIF4E in HL-60 cells.”
BackgroundInfluentialMETTL3 drives NSCLC metastasis by enhancing CYP19A1 translation and oestrogen synthesis
Meng, W., Xiao, H., Zhao, R., Chen, J., Wang, Y., Mei, P., Li, H., & Liao, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01194-9 · Cited by 16
“…of translation. eIF4E, as a cap-binding subunit of the eIF4F complex, is essential for cap-dependent translation of all nuclear-encoded mRNAs [38, 39]. eIF3e, as a subunit of the eIF3 complex, promotes the interaction between MNKs and eIF4G, leading to phosphorylation of eIF4E by MNKs and…”
BackgroundPTBP1 and Cancer: From RNA Regulation to Therapeutic Potential
Ji, C., Zhu, J., Hou, X., Zhou, C., Zhao, J., Zheng, X., & Tang, Y. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70675 · Cited by 17
“RBPs, such as the 5′ cap-binding complex eIF4F and poly A-binding protein (PABP), are required for mRNA cyclization and translational activation [122].”
Golojuch, S., Kopcial, M., Strzelecka, D., Kasprzyk, R., Baran, N., Sikorski, P. J., Kowalska, J., & Jemielity, J. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115523 · Cited by 16
Hypusine Signaling Promotes Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension
Lemay, S.-E. S., Grobs, Y., Romanet, C., Martineau, S., Salem, M., Shimauchi, T., Breuils‐Bonnet, S., Bourgeois, A., Théberge, C., Pelletier, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202305-0909oc · Cited by 16
Reactive oxygen species driven prodrug-based nanoscale carriers for transformative therapies
Vasvani, S., Vasukutty, A., Bardhan, R., Park, I., & Uthaman, S. (2024) · Biomaterials Science · doi:10.1039/d4bm00647j · Cited by 16
IDH1 fine-tunes cap-dependent translation initiation
Liu, L., Lu, J. Y., Li, F., Xing, X., Li, T., Yang, X., & Shen, X. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz082 · Cited by 16
“Translation is one of the most energy-consuming processes in cells, and its dysregulation usually causes neoplastic diseases (Bhat et al., 2015; Truitt and Ruggero, 2017; Robichaud et al., 2019).”
Upregulated expression of eIF3C is associated with malignant behavior in renal cell carcinoma
Fan, M., Wang, K., Wei, X., Yao, H., Chen, Z., & He, X. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4903 · Cited by 16
“During carcinogenesis and tumor progression, gene transcription and protein translation are usually upregulated in tumor cells (18).”
BackgroundSkeparnias, I., Anastasakis, D. G., Grafanaki, K., Kyriakopoulos, G. C., Alexopoulos, P., Dougenis, D., Scorilas, A., Kontos, C. K., & Stathopoulos, C. (2020) · Cancers · doi:10.3390/cancers12103056 · Cited by 16
Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin
Xu, Y., Liao, S., Wang, L., Wang, Y., Wei, W., Su, K., Tu, Y., & Zhu, S. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04195-w · Cited by 16
Qin, S., Huang, H., Xiao, W., Chen, K., He, X., Tang, X., Huang, Z., Zhang, Y., Duan, X., Fan, N., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.010 · Cited by 16
“However, the disadvantage of protein vaccines is the instability and complex manufacturing process compared to mRNA vaccines 68 e 70 .”
BackgroundRust, A., Shah, S. H., Hautbergue, G. M., & Davletov, B. A. (2018) · Toxins · doi:10.3390/toxins10070261 · Cited by 16
“Translation initiation is the rate limiting step of protein synthesis and is up-regulated in most cancers, contributing to increased levels proteins involved in a number of oncogenic processes [7].”
BackgroundKasprzyk, R., Starek, B. J., Ciechanowicz, S., Kubacka, D., Kowalska, J., & Jemielity, J. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201900051 · Cited by 16
Wang, X., Elshahawi, S. I., Ponomareva, L. V., Ye, Q., Liu, Y., Copley, G. C., Hower, J. C., Hatcher, B. E., Kharel, M. K., Lanen, S. G. V., et al. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01015 · Cited by 16
Zhu, X., Dahlmans, V. E. H., Thali, R. F., Preisinger, C., Viollet, B., Voncken, J. W., & Neumann, D. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.c116.740498 · Cited by 16
“Deregulation of eIF4E has been linked to tumorigenesis (26, 27); inhibition of protein translation, e.”
BackgroundHigh-Throughput CRISPR Screening in Hematological Neoplasms
Ancos-Pintado, R., Bragado-García, I., Morales, M. L., García-Vicente, R., Arroyo-Barea, A., Rodríguez-García, A., Martínez-López, J., Linares, M., & Hernández-Sánchez, M. (2022) · Cancers · doi:10.3390/cancers14153612 · Cited by 15
Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
Ruan, H., Leibowitz, B. J., Peng, Y., Shen, L., Chen, L., Kuang, C., Schoen, R. E., Lu, X., Zhang, L., & Yu, J. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00070-7 · Cited by 15
“For example, inhibitors against mRNA Cap binding, eIF4A helicase [7, 8], or p-eIF2α inducing agents such as proteasome (Bortezomib and Ixazomib) [12, 22] and HSP90 inhibitors [23, 24], lack potency or selectivity.”
BackgroundInfluentialJiao, D., Sun, H., Zhao, X., Chen, Y., Lv, Z., Shi, Q., Li, Y., Wang, C., & Gao, K. (2023) · eLife · doi:10.7554/elife.92236 · Cited by 15
“Enhanced protein synthesis is a critical process that allows cancer cells to survive, multiply, metasta-size, and resist anti-cancer treatments ( Bhat et al., 2015 ; Fabbri et al., 2021 ).”
BackgroundeIF4F complex dynamics are important for the activation of the integrated stress response
Kim, K. Q., Urs, A. N. N., Lasehinde, V., Greenlaw, A. C., Hudson, B. H., & Zaher, H. S. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.016 · Cited by 15
“71,72 However, many studies have limited their focus to specific transcripts and the features that allow them to evade cap dependence during initiation.”
BackgroundeIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations
Valčíková, B., Vadovičová, N., Smolkova, K., Zacpalova, M., Krejčí, P., Lee, S., Rauch, J., Kölch, W., von Kriegsheim, A., Dorotikova, A., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321305121 · Cited by 15
“The eukaryotic translation initiation factor eIF4F is a promising therapeutic target in various human cancers ( 9 ).”
BackgroundProtein functional effector sncRNAs (pfeRNAs) in lung cancer
Brock, M. V., & Mei, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.013 · Cited by 15
Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential
Digregorio, M., Lombard, A., Lumapat, P. N., Felix, S., Rogister, B., & Coppieters, N. (2019) · Cells · doi:10.3390/cells8121542 · Cited by 15
“Thus, targeting the protein synthesis pathway has been postulated as an interesting new therapeutic avenue for several types of cancer [10,11].”
BackgroundKinase inhibitors with viral oncolysis: Unmasking pharmacoviral approaches for cancer therapy
Gilchrist, V. H., Jémus-Gonzalez, E., Said, A., & Alain, T. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.07.008 · Cited by 15
Inhibition MNK‐eIF4E‐β‐catenin preferentially sensitizes gastric cancer to chemotherapy
Yang, X., Liu, Z., Yin, X., Zeng, Y., & Guo, G. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12759 · Cited by 15
“Not surprisingly, eIF4E overexpression and activation contributes to aberrant proliferation, survival, metastasis, and resistance to therapy in many cancers, including gastric cancer [7, 8].”
BackgroundInhibition of eIF6 Activity Reduces Hepatocellular Carcinoma Growth: An In Vivo and In Vitro Study
Scagliola, A., Miluzio, A., Mori, G., Ricciardi, S., Oliveto, S., Manfrini, N., & Biffo, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147720 · Cited by 15
Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma
Temblador, A., Topalis, D., Andreï, G., & Snoeck, R. (2022) · Tumour Virus Research · doi:10.1016/j.tvr.2022.200244 · Cited by 15
“mTOR presents two different complexes: mTORC1, which is directly involved in regulation of mRNA translation through the phosphorylation of eIF4E-binding proteins (4E-BPs), and mTORC2, that controls cell survival through Akt activity [23].”
BackgroundReview: New horizons in retinoblastoma treatment: an updated review article.
Azimi, F., Mirshahi, R., & Naseripour, M. (2022) · PubMed Central · Cited by 15
Inhibition of Mnk–eIF4E Pathway Sensitizes The Efficacy to Chemotherapy in Anaplastic Thyroid Cancer
Hu, K., Zhang, J., Yu, M., & Xiong, C. (2016) · Future Oncology · doi:10.2217/fon-2016-0320 · Cited by 15
Wilde, B. R., Kaadige, M. R., Guillen, K. P., Butterfield, A., Welm, B. E., & Ayer, D. E. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00233-6 · Cited by 15
Turovsky, E. A., Plotnikov, E. Y., Simakin, A. V., Gudkov, S. V., & Varlamova, E. G. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110241 · Cited by 14
Delgado, M. E., Naranjo‐Suarez, S., Ramírez-Pedraza, M., Cárdenas, B., Gallardo-Martínez, C., Balvey, A., Belloc, E., Martín, J., Boyle, M., Méndez, R., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101296 · Cited by 14
Inhibitory effects of Tomivosertib in acute myeloid leukemia
Suárez, M., Blyth, G. T., Mina, A. A., Kościuczuk, E. M., Dolniak, B., Dinner, S. N., Altman, J. K., Eklund, E. A., Saleiro, D., Beauchamp, E. M., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27952 · Cited by 14
“Protein synthesis is commonly dysregulated in solid tumors and hematological malignancies [47, 48].”
BackgroundPolysome Fractionation for Transcriptome-Wide Studies of mRNA Translation
Ristau, J., Watt, K., Oertlin, C., & Larsson, O. S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1920-9_14 · Cited by 14
Kondoh, K., Akahori, H., Muto, Y., & Terada, T. (2022) · Genes · doi:10.3390/genes13112134 · Cited by 14
Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art
Zhang, H., Cai, J., Yu, S., Sun, B., & Zhang, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065184 · Cited by 14
Cooperative activation of PDK1 and AKT by MAPK4 enhances cancer growth and resistance to therapy
Han, D., Wang, W., Jeon, J. H., Shen, T., Huang, X., Yi, P., Dong, B., & Yang, F. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002227 · Cited by 14
Hsieh, C.-H., Huang, C.-T., Cheng, Y., Hsu, C., Hsu, W., Chung, Y.-H., Liu, Y., Yang, T., Chien, C., Lee, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115429 · Cited by 14
Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly
Frosi, Y., Usher, R., Lian, D. T. G., Lane, D. P., & Brown, C. J. (2019) · BMC Biology · doi:10.1186/s12915-019-0658-0 · Cited by 14
Kasprzyk, R., Kowalska, J., Wieczorek, Z. J., Szabelski, M., Stolarski, R., & Jemielity, J. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00419a · Cited by 14
Targeting EIF4F complex in non-small cell lung cancer cells
Dai, L., Lin, Z. N., Cao, Y., Chen, Y., Xu, Z., & Qin, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.18413 · Cited by 14
“As the components of the translation machinery integrate almost all oncogenic signals [9], targeting the EIF4F complex components holds the promise for overcoming a major hurdle associated with intra-tumor heterogeneity.”
BackgroundInfluentialMetabolism and mRNA translation: a nexus of cancer plasticity
Tang, X., Li, K., Wang, Y., Rocchi, S., Shen, S., & Cerezo, M. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.009 · Cited by 13
lncRNAs: the unexpected link between protein synthesis and cancer adaptation
Gugnoni, M., Kashyap, M. K., Wary, K. K., & Ciarrocchi, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02236-7 · Cited by 13
O’Rourke, R. L., & Garner, A. L. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00674 · Cited by 13
The proteostasis network is a therapeutic target in acute myeloid leukemia
Lam, K., Kim, Y. J., Tan, E. L., Ong, C. M., Liu, A. Z., Zhou, F., Sunshine, M. J., Chua, B. A., Vicenzi, S., Chen, K., et al. (2025) · Blood · doi:10.1182/blood.2024026749 · Cited by 13
Cumulative evidence of relationships between multiple variants in 8q24 region and cancer incidence
Yu, T., Tang, Y., Li, S., Zhao, F., Ying, J., Qu, Y., Niu, X., & Mu, D. (2020) · Medicine · doi:10.1097/md.0000000000020716 · Cited by 13
“Identification of genetic factors regulating the development and progression of cancers contributes to improvement of preventive measures and therapeutic outcomes.([1]) Genome-wide association studies (GWAS) have identified multiple independent cancer susceptibility loci at chromosome 8q24.”
BackgroundThe Use of Peptides in the Treatment of Fragile X Syndrome: Challenges and Opportunities
Romagnoli, A., & Marino, D. D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.754485 · Cited by 13
“All the strategies mentioned so far target different pathways, whose uncontrolled activity seems to be crucial in the pathology of FXS, but also in other neurological disorders and types of cancer (108, 109), leading to pleiotropic effects.”
BackgroundLuu, A. K., Cadieux, M., Wong, M., Macdonald, R., Jones, R., Choi, D., Oblak, M. L., Brisson, B. A., Sauer, S. J., Chafitz, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063256 · Cited by 13
LINC02870 facilitates SNAIL translation to promote hepatocellular carcinoma progression
Guo, M., Zhuang, H., Huang, J., Shao, X., Bai, N., Li, M., Niu, M., Wei, W., Sun, L., Li, Y., et al. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04575-1 · Cited by 13
eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma
Steinmann, S. M., Sánchez-Martín, A., Tanzer, E., Cigliano, A., Pes, G. M., Simile, M. M., Désaubry, L., Marín, J. J. G., Evert, M., & Calvisi, D. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032055 · Cited by 13
Hung, Y., Ouyang, C., Ping, X., Qi, Y., Wang, Y.-C., Kung, H.-J., & Ann, D. K. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00924-4 · Cited by 13
“Results from several studies have shown that tumor phenotype is driven not only by global changes in protein synthesis, but also by selective changes in translational efficiency [6].”
BackgroundGu, J., Han, F., Chen, S., & Zhang, Q. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06324-x · Cited by 13
“times the square root of the number of papers published by the most prolific scientists [40].”
BackgroundDeveloping anti-neoplastic biotherapeutics against eIF4F
Steinberger, J., Chu, J., Maïga, R. I., Sleiman, K., & Pelletier, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2430-8 · Cited by 13
Self-citationChu, J., y Cajal, S. R., Sonenberg, N., & Pelletier, J. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.11.002 · Cited by 13
“Increased signalling flux through the PI3K/ mTOR pathway leads to mTOR phosphorylation of 4E-BP, which in turn releases eIF4E and allows it to enter the eIF4F complex [15,17].”
BackgroundInfluentialSelf-citationTracing MYC Expression for Small Molecule Discovery
Steinberger, J., Robert, F., Hallé, M., Williams, D. E., Cencic, R., Sawhney, N., Pelletier, D., Williams, P. G., Igarashi, Y., Porco, J. A. J., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.007 · Cited by 13
Self-citationCarvalho, A., Viaene, J., Vandenbussche, G., Braekeleer, K. D., Masereel, B., Wouters, J., Souard, F., Heyden, Y. V., Antwerpen, P. V., Delporte, C., et al. (2019) · Drug Development Research · doi:10.1002/ddr.21600 · Cited by 13
“Such strategies include inhibition of specific targets in the translation machinery (ItouaMaïga et al., 2019) as well as inhibitors of upstream signaling pathways involved at different stages of cancer development (Bhat et al., 2015; Xie, Merrett, Jensen, & Proud, 2019).”
BackgroundMultifaceted control of mRNA translation machinery in cancer
Alboushi, L., Hackett, A. P., Naeli, P., Bakhti, M., & Jafarnejad, S. M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110037 · Cited by 13
Cancer Stem Cells Contribute to Drug Resistance in Multiple Different Ways
Zahra, M. H., Nawara, H. M., Hassan, G., Afify, S. M., Seno, A., & Seno, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-12974-2_6 · Cited by 13
Sommer, G., Fedarovich, A., Kota, V., Rodriguez, R., Smith, C. D., & Heise, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173246 · Cited by 13
Li, L., Lu, H., Binu, W., Xinxin, D., Longjun, W., Liping, Y., & Yingying, Z. (2018) · Medical Science Monitor · doi:10.12659/msm.910702 · Cited by 12
“These genes and pathways are considered important therapeutic targets for the treatment of cancers [23].”
BackgroundRetracted
Metadata
- Authors
- Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Jewish General Hospital (CA)
- Corresponding author
- Sonenberg, Nahum
- Pelletier, Jerry
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-03-06
- Volume
- 14
- Issue
- 4
- Pages
- 261-278
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2040885133
- Cited by
- 799
- References
- 291
- Citations by year
- 2026: 40 · 2025: 44 · 2024: 69 · 2023: 77 · 2022: 58 · 2021: 75 · 2020: 92 · 2019: 70 · 2018: 89 · 2017: 99 · 2016: 65 · 2015: 19
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@McGill (McGill) (submittedVersion)
- Funders
- Howard Hughes Medical Institute (55007654)
- Canadian Institutes of Health Research (MOP115-195, MOP#115126, 106530_1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Keywords
- mRNA translation, translation machinery, cancer, eIF4F, translation initiation, oncogenes, tumour suppressor, anticancer agents, intra-tumour heterogeneity, drug development
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, RNA, Messenger, Protein Biosynthesis, Gene Expression Regulation, Neoplastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.